磺达肝癸钠预防脊柱椎管减压术后静脉血栓栓塞的临床研究

Clinical Study on Prevention of VTE after Spinal Canal Decompression with Fondaparinux

目的探讨脊柱椎管减压术后用磺达肝葵钠预防静脉血栓栓塞症(VTE)的临床有效性及安全性。方法分析我院2022年6月至2023年6月行脊柱椎管减压术需抗凝治疗的患者100例,A组50例选用低分子肝素钙皮下注射,B组50例选用磺达肝葵钠皮下注射。观察患者一般情况、实验室检查、血管彩超,对术后患者静脉血栓情况进行评价。结果所有患者均获随访,随访时间为6~12个月,平均8个月。两组患者均未发生静脉血栓,两组术后引流量、血小板计数、凝血时间、术后并发症无明显差异(均P>0.05)。结论脊柱椎管减压术后应用磺达肝葵钠预防VTE安全有效,但需密切观察,注意患者出血等高危因素。

Objective To investigate clinical efficacy and safety of fondaparinux for preventing venous thrombosis after spinal canal decompression.Methods From June 2022 to June 2023,100 patients who underwent spinal canal decompression in our hospital requiring anticoagulant treatment were analyzed.50 cases in group A were given subcutaneous injection of low molecular weight heparin calcium,and 50 cases in group B were given subcutaneous injection offondaparinux.General condition,laboratory examination and color doppler ultrasound were observed,and the venous thrombosis was evaluated.Results All patients were followed up for 6-12 months with an average of 8 months.No venous thrombosis occurred,and no significant difference was observed between two groups(all P>0.05).Conclusion It is safe and effective to prevent VET with fondaparinux after spinal canal decompression,but it is necessary to pay close attention to the high risk factors of bleeding.